GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (NAS:OPTN) » Definitions » Piotroski F-Score

OptiNose (OptiNose) Piotroski F-Score

: 3 (As of Today)
View and export this data going back to 2017. Start your Free Trial

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

OptiNose has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for OptiNose's Piotroski F-Score or its related term are showing as below:

OPTN' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 3

During the past 9 years, the highest Piotroski F-Score of OptiNose was 5. The lowest was 2. And the median was 4.


OptiNose Piotroski F-Score Historical Data

The historical data trend for OptiNose's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptiNose Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 2.00 4.00 4.00 3.00

OptiNose Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 3.00 4.00 3.00

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, OptiNose's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OptiNose Piotroski F-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, OptiNose's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where OptiNose's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -18.847 + 2.626 + -9.294 + -9.967 = $-35.48 Mil.
Cash Flow from Operations was -10.478 + -12.538 + -4.425 + 6.909 = $-20.53 Mil.
Revenue was 11.846 + 19.454 + 19.823 + 19.865 = $70.99 Mil.
Gross Profit was 10.14 + 16.883 + 17.598 + 17.734 = $62.36 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(144.222 + 114.925 + 106.068 + 101.407 + 107.729) / 5 = $114.8702 Mil.
Total Assets at the begining of this year (Dec22) was $144.22 Mil.
Long-Term Debt & Capital Lease Obligation was $0.61 Mil.
Total Current Assets was $105.33 Mil.
Total Current Liabilities was $176.52 Mil.
Net Income was -25.333 + -19.397 + -14.954 + -15.149 = $-74.83 Mil.

Revenue was 14.76 + 20.582 + 20.078 + 20.856 = $76.28 Mil.
Gross Profit was 12.746 + 18.439 + 17.953 + 17.875 = $67.01 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(166.071 + 133.815 + 122.832 + 105.27 + 144.222) / 5 = $134.442 Mil.
Total Assets at the begining of last year (Dec21) was $166.07 Mil.
Long-Term Debt & Capital Lease Obligation was $0.63 Mil.
Total Current Assets was $140.48 Mil.
Total Current Liabilities was $178.73 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

OptiNose's current Net Income (TTM) was -35.48. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

OptiNose's current Cash Flow from Operations (TTM) was -20.53. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-35.482/144.222
=-0.24602349

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-74.833/166.071
=-0.45060847

OptiNose's return on assets of this year was -0.24602349. OptiNose's return on assets of last year was -0.45060847. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

OptiNose's current Net Income (TTM) was -35.48. OptiNose's current Cash Flow from Operations (TTM) was -20.53. ==> -20.53 > -35.48 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0.611/114.8702
=0.00531905

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0.625/134.442
=0.00464884

OptiNose's gearing of this year was 0.00531905. OptiNose's gearing of last year was 0.00464884. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=105.333/176.524
=0.5967064

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=140.484/178.73
=0.78601242

OptiNose's current ratio of this year was 0.5967064. OptiNose's current ratio of last year was 0.78601242. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

OptiNose's number of shares in issue this year was 112.331. OptiNose's number of shares in issue last year was 95.06. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=62.355/70.988
=0.8783879

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=67.013/76.276
=0.87855944

OptiNose's gross margin of this year was 0.8783879. OptiNose's gross margin of last year was 0.87855944. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=70.988/144.222
=0.49221339

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=76.276/166.071
=0.45929753

OptiNose's asset turnover of this year was 0.49221339. OptiNose's asset turnover of last year was 0.45929753. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+0+0+0+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

OptiNose has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

OptiNose  (NAS:OPTN) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


OptiNose Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of OptiNose's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


OptiNose (OptiNose) Business Description

Traded in Other Exchanges
Address
1020 Stony Hill Road, Suite 300, Yardley, PA, USA, 19067
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
Executives
Marino Michael F Iii officer: Chief Legal Officer & Corp Sec C/O NUPATHE, INC., 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Ramy A Mahmoud officer: President & COO 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Peter K Miller director, officer: Chief Executive Officer C/O INTERNET CAPITAL GROUP, 690 LEE ROAD, SUITE 310, WAYNE PA 19087
Mvm Partners, Llc 10 percent owner OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Michele Janis officer: Acting Chief Financial Officer 1020 STONY HILL ROAD, YARDLEY PA 19067
Victor M Clavelli officer: Chief Commercial Officer 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Paul Jr. Spence officer: Chief Commercial Officer 1507 POWNAL DRIVE, YARDLEY PA 19067
Anthony J Krick officer: Chief Accounting Officer 1020 STONY HILL ROAD, YARDLEY PA 19067
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Kyle Dempsey director OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Eric Bednarski director OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Partners Llp Mvm 10 percent owner 30 ST. GEORGE STREET, LONDON X0 W1S SFH
Keith A. Goldan officer: Chief Financial Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Joseph C Scodari director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080